{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["103(9)"],"submitter":["Goede V"],"pubmed_abstract":["Background
The combination of chemotherapy with the vascular endothelial growth factor (VEGF) antibody bevacizumab is a standard of care in advanced colorectal cancer (CRC). However, biomarkers predicting outcome of bevacizumab-containing treatment are lacking. As angiopoietin-2 (Ang-2) is a key regulator of vascular remodelling in concert with VEGF, we investigated its role as a biomarker in metastatic CRC.Methods
Serum Ang-2 levels were measured in 33 healthy volunteers and 90 patients with CRC. Of these, 34 had metastatic disease and received bevacizumab-containing therapy. To determine the tissue of origin of Ang-2, quantitative real-time PCR was performed on microdissected cryosections of human CRC and in a murine xenograft model of CRC using species-specific amplifica"],"journal":["British journal of cancer"],"pagination":["1407-14"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2990609"],"repository":["biostudies-literature"],"pubmed_title":["Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy."],"pmcid":["PMC2990609"],"pubmed_authors":["Koslowsky TC","Schnell R","Coutelle O","Reinacher-Schick A","Hacker UT","Odenthal M","Schmiegel W","Neuneier J","Kashkar H","Hallek M","Weihrauch MR","Goede V","Cremer B","Augustin HG"],"additional_accession":[]},"is_claimable":false,"name":"Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.","description":"Background
The combination of chemotherapy with the vascular endothelial growth factor (VEGF) antibody bevacizumab is a standard of care in advanced colorectal cancer (CRC). However, biomarkers predicting outcome of bevacizumab-containing treatment are lacking. As angiopoietin-2 (Ang-2) is a key regulator of vascular remodelling in concert with VEGF, we investigated its role as a biomarker in metastatic CRC.Methods
Serum Ang-2 levels were measured in 33 healthy volunteers and 90 patients with CRC. Of these, 34 had metastatic disease and received bevacizumab-containing therapy. To determine the tissue of origin of Ang-2, quantitative real-time PCR was performed on microdissected cryosections of human CRC and in a murine xenograft model of CRC using species-specific amplifica","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Oct","modification":"2025-04-04T19:42:35.42Z","creation":"2019-03-27T00:36:51Z"},"accession":"S-EPMC2990609","cross_references":{"pubmed":["20924372"],"doi":["10.1038/sj.bjc.6605925"]}}